Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX
Quoin Pharmaceuticals — Investor Presentation (August 2026)
26 slides from Quoin Pharmaceuticals's investor presentation, August 2026
Slide 1: Corporate Overview: Non-Confidential
Corporate Overview: Non-Confidential August 2026 quoinpharma.com
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, which are based on our management’s You should refer to “Risk Factors” in our Annual Report on Form 10-K for the current beliefs, expectations and assumptions about future events, conditi
Slide 3: Robust Development Pipeline
Robust Development Pipeline Two differentiated products. Each exceeding $1Bn opportunities QRX003 QRX009 Topical Lotion Topical Lotion & Patch Netherton Syndrome* Phase 2/3 Pachyonychia Congenita* Phase 1 Gorlin Syndrome* Phase 1 Peeling Skin Syndrome** Phase 2 Tuberous Sclerosis Complex* Phase 1 SA
Slide 4: Netherton Syndrome (NS)
Netherton Syndrome (NS) NS is caused by a mutation of the SPINK5 (serine protease inhibitor, Kazal Type 5) gene SPINK5 mutations LEKTI 1 Antimicrobial Corneodesmosomes Kallikreins Infections Peptides Stratum corneum Lipid processing enzymes IL-1α activated cohesion Thinning (loss) of Lamellar bilaye
Slide 5: Netherton Syndrome
Netherton Syndrome 6000 – 8000 1 in 100,00- Patients in US and Europe Combined. 200,000 Up to 30,000 in Quoin Partnered Territories Newborns affected • No Approved Treatment or • Can be hospitalized on Cure multiple occasions • Patients suffer from multiple annually severe issues: • Patients current
Slide 6: QRX003 Mechanism of Action
QRX003 Mechanism of Action • Topical lotion to be applied twice-daily • Restores natural balance of skin shedding and to whole body surface regeneration that is disrupted by the absence of LEKTI in NS patients • Enables skin to fully heal and eliminates key • QRX003 performs the function of the symp
Slide 7: Clinical Development Overview
Clinical Development Overview Number of Study Number Study Stage Status Design Patients CL-QRX003-001 ** POC- Monotherapy Completed 13 Vehicle controlled* CL-QRX003-002A/B** POC- Adjuvant Therapy Completed 8 Open Label, Baseline Controlled CL-QRX003-002C P2-Adjuvant Ongoing 8 Open Label, Baseline Co
Slide 8: POC 2: Open Label Study: Part A/B
POC 2: Open Label Study: Part A/B All subjects taking off-label systemic biologics prior to and during study Part A • Single Arm, Open Label, No vehicle control • 2% dose QD on approx. 20% BSA (arms or lower legs) • 12 weeks duration, final visit week 16 • 7 subjects recruited • Dosed at 25% of curr
Slide 9: Open Label POC Study: Part A
Open Label POC Study: Part A 7 Subjects Recruited Not powered to detect differences in endpoints Results: IGA: (Scale 0-4) • 2 of 7 had a minimum of 1 grade improvement from baseline Pruritus • 5 of 7 had a two-point improvement (p=0.001) • 3 of 5 had a four-point improvement (p=0.0579) • Mean chang
Slide 10: Open Label POC Study: Part B
Open Label POC Study: Part B • Single Arm, Open Label, No vehicle control • 4% dose BD on approx. 20% BSA (arms or lower legs) • 12 weeks duration, final visit week 16 • 1 subject recruited • Dose was the same as current whole-body treatment
Slide 11: Open Label POC Study Part B
Open Label POC Study Part B One Subject: 12 Weeks Twice Daily Dosing, 20% BSA End Point Baseline 6 weeks 12weeks M-IASI* 18 4 3 WINRS** 7 4 2 IGA*** Moderate Mild Almost Clear PASA Highly positive across all timepoints Key Findings • Marked improvements observed across all measured clinical endpoint
Slide 12: Open Label POC Study: Part B - Results
Open Label POC Study: Part B - Results Twice Daily dosing images Baseline 12 weeks 12
Slide 13: Open Label POC Study Data - Part B
Open Label POC Study Data- Open Label Study Part B One Subject: 4 weeks after Discontinuation of Treatment 16 weeks End Point Baseline 6 weeks 12weeks (4 weeks after discontinuation of treatment) M-IASI* 18 4 3 18 WINRS** 7 4 2 8 IGA*** Moderate Mild Almost Clear Moderate PASA Highly positive across
Slide 14: Pediatric Compassionate Use Program
Pediatric Compassionate Use Program Results to Date: • 4 of 6 subjects classified as “Improved” or “Significantly Improved” IGA 4 grade IGA 1-2 grade IGA 0 grade improvement improvement improvement Number of responders 1 3 2 WINRS 4 grade WINRS 0 grade WINRS 1 at baseline improvement improvement and
Slide 15: Pediatric Patient 1, 9 months testing
Pediatric Patient 1, 9 months testing End Point* Baseline 6 weeks 9 months IGA 4 (severe) 1 (almost clear) 0 (clear) Pruritus 5 1 0 • Patient discontinued previously required medications including all antihistamines, glucocorticoids and antivirals. • Patient has required no antibiotics since the who
Slide 16: Commercialization Readiness
Commercialization Readiness Planned Commercial Footprint: Approximately 30 FTEs Pricing: Working with commercial consultants to finalize pricing strategy based on actual claims and payer data 9 Partnerships across Branding: 61 other countries INN/ USAN and brand name development complete Market Oppo
Slide 17: Peeling Skin Syndrome
Peeling Skin Syndrome • IND Submitted June 2nd, 2026 • Cleared to proceed July, 2026 • Phase 2: 12 adult and pediatric patients • Clinical sites identified in US and Europe • QRX003 applied twice-daily to greater than 80% of BSA • 52-week study with interim analysis Corporate Overview: Non-Confident
Slide 18: First Subject Peeling Skin Data
First Subject Peeling Skin Data End Point Baseline 12 weeks 14 months M-IASI* 36 12 3.4 IGA** 4 (Severe) 2 (Mild) 2 (Mild) CDQLI*** 19 11 12 • Subject continues to improve through 15 months *M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin sy
Slide 19: Peeling Skin Commercial Opportunity
Peeling Skin Commercial Opportunity • Ultra-rare disease with prevalence of less than 1 in 1000000, though thought to be significantly underdiagnosed • Additive to Netherton Syndrome leveraging the same infrastructure and call points • No additional resources required from a commercial perspective •
Slide 20: QRX009 Clinical Programs
QUOIN PHARMACEUTICALS QRX009 Clinical Programs
Slide 21: QRX009: Topical Rapamycin Programs
QRX009: Topical Rapamycin Programs Two Distinct Approaches Part A Part B • Investigator Studies conducted by • Formal Regulatory Studies leading KOLs Corporate Overview: Non-Confidential - 21
Slide 22: QRX009: Topical Rapamycin Programs - Investigator Led Studies
QRX009: Topical Rapamycin Programs Part A. Investigator Led Studies: • POC Study in Pachyonychia Congenita (PC) to commence in 2H 2026 • Gorlin Syndrome and Tuberous Sclerosis Complex (TSC) POC studies in 2027 • Studies Conducted by Leading Global KOLs • Strong support from Advocacy Foundations • Ta
Slide 23: QRX009: Topical Rapamycin Programs - IND Studies
QRX009: Topical Rapamycin Programs Part B. IND Studies: • Targeting IND Submission for one indication in 1H 2027 • Microcystic Lymphatic Malformations, Venous Malformations, Serious Angiokeratomas • Initiate P2 Study for one indication in 1H 2027 Corporate Overview: Non-Confidential - 23
Slide 24: Company Highlights
Company Highlights QRX003 Netherton Syndrome & Peeling Skin Syndrome QRX009 Topical Rapamycin Programs • Netherton Syndrome: late-stage lead program advancing to pivotal • Topical rapamycin platforms (proprietary lotion and dermal patch) trials • Investigator-led study in Pachyonychia Congenita led
Slide 25: Strong Management Team with Proven Track Record of Success
Strong Management Team with Proven Track Record of Success Name Position Experience Dr. Michael Myers CEO Denise Carter COO Sally Lawlor CFO Seasoned executives with over 90 years experience developing products based on drug delivery technologies Corporate Overview: Non-Confidential - 25
Slide 26: Thank You
THANK YOU quoinpharma.com
Quoin Pharmaceuticals — Investor Presentation (August 2026) on 6ix